Fmr LLC Sells 437,232 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Fmr LLC lowered its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 12.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,982,549 shares of the company’s stock after selling 437,232 shares during the period. Fmr LLC owned about 2.83% of MaxCyte worth $11,602,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Marshall Wace LLP acquired a new stake in shares of MaxCyte in the 2nd quarter valued at $1,959,000. Royce & Associates LP boosted its position in MaxCyte by 59.8% in the third quarter. Royce & Associates LP now owns 323,924 shares of the company’s stock valued at $1,260,000 after buying an additional 121,272 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in MaxCyte by 13.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock worth $3,961,000 after buying an additional 121,090 shares during the last quarter. River Global Investors LLP increased its holdings in shares of MaxCyte by 4.7% during the third quarter. River Global Investors LLP now owns 2,062,562 shares of the company’s stock worth $8,034,000 after buying an additional 93,340 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of MaxCyte by 24.4% during the second quarter. Bank of New York Mellon Corp now owns 423,209 shares of the company’s stock worth $1,659,000 after buying an additional 83,025 shares in the last quarter. Institutional investors own 68.81% of the company’s stock.

Insiders Place Their Bets

In other news, Director Stanley C. Erck sold 21,607 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the completion of the transaction, the director now directly owns 269,118 shares in the company, valued at approximately $998,427.78. The trade was a 7.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 27,607 shares of company stock valued at $102,782. 3.00% of the stock is currently owned by insiders.

MaxCyte Price Performance

Shares of MXCT opened at $4.43 on Thursday. The company has a market capitalization of $468.21 million, a P/E ratio of -12.32 and a beta of 1.37. MaxCyte, Inc. has a one year low of $3.16 and a one year high of $5.55. The business’s 50 day simple moving average is $3.66 and its 200-day simple moving average is $4.06.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $8.16 million for the quarter, compared to analyst estimates of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same period in the prior year, the business earned ($0.11) earnings per share. On average, sell-side analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.